{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T03:22:46Z","timestamp":1790133766823,"version":"4.0.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370194"],"award-info":[{"award-number":["82370194"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200887"],"award-info":[{"award-number":["82200887"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2022M7114034"],"award-info":[{"award-number":["2022M7114034"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023M741463"],"award-info":[{"award-number":["2023M741463"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01450-w","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:05:58Z","timestamp":1770815158000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Penpulimab combined with rituximab, high-dose methotrexate, and cytarabine (Pen-RMA) in newly diagnosed primary central nervous system lymphoma (PCNSL): a phase 2 trial"],"prefix":"10.1038","volume":"16","author":[{"given":"Hao-Rui","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Zhu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Xin","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luthuli","family":"Sibusiso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Fan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Lin","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9931-4055","authenticated-orcid":false,"given":"Jian-Yong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Hua","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4208-7477","authenticated-orcid":false,"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"1450_CR1","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1200\/JCO.2017.72.7602","volume":"35","author":"C Grommes","year":"2017","unstructured":"Grommes C, DeAngelis LM. Primary CNS lymphoma. J Clin Oncol. 2017;35:2410\u20138.","journal-title":"J Clin Oncol"},{"key":"1450_CR2","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36:1720\u201348.","journal-title":"Leukemia"},{"key":"1450_CR3","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1182\/bloodadvances.2016000927","volume":"1","author":"J Fallah","year":"2016","unstructured":"Fallah J, Qunaj L, Olszewski AJ. Therapy and outcomes of primary central nervous system lymphoma in the United States: analysis of the National Cancer Database. Blood Adv. 2016;1:112\u201321.","journal-title":"Blood Adv"},{"key":"1450_CR4","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s11060-010-0269-7","volume":"101","author":"AD Norden","year":"2011","unstructured":"Norden AD, Drappatz J, Wen PY, Claus EB. Survival among patients with primary central nervous system lymphoma, 1973-2004. J Neurooncol. 2011;101:487\u201393.","journal-title":"J Neurooncol"},{"key":"1450_CR5","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","volume":"3","author":"AJ Ferreri","year":"2016","unstructured":"Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016;3:e217\u201327.","journal-title":"Lancet Haematol"},{"key":"1450_CR6","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1093\/neuonc\/noad224","volume":"26","author":"JEC Bromberg","year":"2024","unstructured":"Bromberg JEC, Issa S, van der Holt B, van der Meulen M, Dirven L, Minnema MC, et al. Survival, neurocognitive function, and health-related quality of life outcomes after rituximab-methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: final results of the HOVON 105\/ALLG NHL 24 study. Neuro Oncol. 2024;26:724\u201334.","journal-title":"Neuro Oncol"},{"key":"1450_CR7","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/S2352-3026(17)30174-6","volume":"4","author":"AJM Ferreri","year":"2017","unstructured":"Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Rosee P, et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol. 2017;4:e510\u2013e23.","journal-title":"Lancet Haematol"},{"key":"1450_CR8","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1182\/blood.2020008377","volume":"140","author":"LR Schaff","year":"2022","unstructured":"Schaff LR, Grommes C. Primary central nervous system lymphoma. Blood. 2022;140:971\u20139.","journal-title":"Blood"},{"key":"1450_CR9","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1182\/bloodadvances.2018027672","volume":"3","author":"N Nayyar","year":"2019","unstructured":"Nayyar N, White MD, Gill CM, Lastrapes M, Bertalan M, Kaplan A, et al. MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas. Blood Adv. 2019;3:375\u201383.","journal-title":"Blood Adv"},{"key":"1450_CR10","doi-asserted-by":"publisher","first-page":"44960","DOI":"10.18632\/oncotarget.16680","volume":"8","author":"P Gravelle","year":"2017","unstructured":"Gravelle P, Burroni B, Pericart S, Rossi C, Bezombes C, Tosolini M, et al. Mechanisms of PD-1\/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies. Oncotarget. 2017;8:44960\u201375.","journal-title":"Oncotarget"},{"key":"1450_CR11","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","volume":"127","author":"B Chapuy","year":"2016","unstructured":"Chapuy B, Roemer MG, Stewart C, Tan Y, Abo RP, Zhang L, et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016;127:869\u201381.","journal-title":"Blood"},{"key":"1450_CR12","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/hon.2375","volume":"35","author":"M Four","year":"2017","unstructured":"Four M, Cacheux V, Tempier A, Platero D, Fabbro M, Marin G, et al. PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival. Hematol Oncol. 2017;35:487\u201396.","journal-title":"Hematol Oncol"},{"key":"1450_CR13","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1080\/10428194.2020.1742903","volume":"61","author":"JJ Graber","year":"2020","unstructured":"Graber JJ, Plato B, Mawad R, Moore DJ. Pembrolizumab immunotherapy for relapsed CNS Lymphoma. Leuk Lymphoma. 2020;61:1766\u20138.","journal-title":"Leuk Lymphoma"},{"key":"1450_CR14","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1182\/blood-2017-01-764209","volume":"129","author":"L Nayak","year":"2017","unstructured":"Nayak L, Iwamoto FM, LaCasce A, Mukundan S, Roemer MGM, Chapuy B, et al. PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma. Blood. 2017;129:3071\u20133.","journal-title":"Blood"},{"key":"1450_CR15","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41392-024-01941-x","volume":"9","author":"Z Zeng","year":"2024","unstructured":"Zeng Z, Yang A, Yang J, Zhang S, Xing Z, Wang X, et al. Sintilimab (anti-PD-1 antibody) combined with high-dose methotrexate, temozolomide, and rituximab (anti-CD20 antibody) in primary central nervous system lymphoma: a phase 2 study. Signal Transduct Target Ther. 2024;9:229.","journal-title":"Signal Transduct Target Ther"},{"key":"1450_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jitc-2019-000437","volume":"8","author":"L Shen","year":"2020","unstructured":"Shen L, Guo J, Zhang Q, Pan H, Yuan Y, Bai Y, et al. Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1\/2 study. J Immunother Cancer. 2020;8:1.","journal-title":"J Immunother Cancer"},{"key":"1450_CR17","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00262-018-2160-x","volume":"67","author":"T Zhang","year":"2018","unstructured":"Zhang T, Song X, Xu L, Ma J, Zhang Y, Gong W, et al. The binding of an anti-PD-1 antibody to FcgammaRIota has a profound impact on its biological functions. Cancer Immunol Immunother. 2018;67:1079\u201390.","journal-title":"Cancer Immunol Immunother"},{"key":"1450_CR18","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/S1470-2045(18)30495-9","volume":"19","author":"W Fang","year":"2018","unstructured":"Fang W, Yang Y, Ma Y, Hong S, Lin L, He X, et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol. 2018;19:1338\u201350.","journal-title":"Lancet Oncol"},{"key":"1450_CR19","doi-asserted-by":"publisher","first-page":"5640","DOI":"10.1182\/blood-2012-01-380121","volume":"119","author":"P Bruhns","year":"2012","unstructured":"Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood. 2012;119:5640\u20139.","journal-title":"Blood"},{"key":"1450_CR20","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1080\/19420862.2015.1022692","volume":"7","author":"M Kinder","year":"2015","unstructured":"Kinder M, Greenplate AR, Strohl WR, Jordan RE, Brezski RJ. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions. MAbs. 2015;7:494\u2013504.","journal-title":"MAbs"},{"key":"1450_CR21","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ccell.2015.08.004","volume":"28","author":"R Dahan","year":"2015","unstructured":"Dahan R, Sega E, Engelhardt J, Selby M, Korman AJ, Ravetch JV. FcgammaRs modulate the anti-tumor activity of antibodies targeting the PD-1\/PD-L1 Axis. Cancer Cell. 2015;28:285\u201395.","journal-title":"Cancer Cell"},{"key":"1450_CR22","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1007\/s40265-021-01640-9","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon S. Penpulimab: first approval. Drugs. 2021;81:2159\u201366.","journal-title":"Drugs"},{"key":"1450_CR23","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","volume":"23","author":"LE Abrey","year":"2005","unstructured":"Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23:5034\u201343.","journal-title":"J Clin Oncol"},{"key":"1450_CR24","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1038\/s41375-024-02279-7","volume":"38","author":"JH Liang","year":"2024","unstructured":"Liang JH, Wu YF, Shen HR, Li Y, Liang JH, Gao R, et al. Clinical implications of CSF-ctDNA positivity in newly diagnosed diffuse large B cell lymphoma. Leukemia. 2024;38:1541\u201352.","journal-title":"Leukemia"},{"key":"1450_CR25","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","volume":"37","author":"GW Wright","year":"2020","unstructured":"Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020;37:551\u201368.","journal-title":"Cancer Cell"},{"key":"1450_CR26","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1007\/s12094-023-03292-5","volume":"26","author":"KX Du","year":"2024","unstructured":"Du KX, Shen HR, Pan BH, Luthuli S, Wang L, Liang JH, et al. Prognostic value of POD18 combined with improved IELSG in primary central nervous system lymphoma. Clin Transl Oncol. 2024;26:720\u201331.","journal-title":"Clin Transl Oncol"},{"key":"1450_CR27","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/bjh.15009","volume":"183","author":"Y Qiu","year":"2018","unstructured":"Qiu Y, Li Z, Pouzoulet F, Vishnu P, Copland JA 3rd, Knutson KL, et al. Immune checkpoint inhibition by anti-PDCD1 (anti-PD1) monoclonal antibody has significant therapeutic activity against central nervous system lymphoma in an immunocompetent preclinical model. Br J Haematol. 2018;183:674\u20138.","journal-title":"Br J Haematol"},{"key":"1450_CR28","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.canlet.2020.12.043","volume":"502","author":"S Zhou","year":"2021","unstructured":"Zhou S, Xie J, Huang Z, Deng L, Wu L, Yu J, et al. Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: mechanisms, advances, and challenges. Cancer Lett. 2021;502:166\u201379.","journal-title":"Cancer Lett"},{"key":"1450_CR29","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","volume":"7","author":"C Grommes","year":"2017","unstructured":"Grommes C, Pastore A, Palaskas N, Tang SS, Campos C, Schartz D, et al. Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma. Cancer Discov. 2017;7:1018\u201329.","journal-title":"Cancer Discov"},{"key":"1450_CR30","doi-asserted-by":"publisher","first-page":"901797","DOI":"10.3389\/fonc.2022.901797","volume":"12","author":"C Yang","year":"2022","unstructured":"Yang C, Cui Y, Ren X, Li M, Yu K, Shen S, et al. Orelabrutinib combined with lenalidomide and immunochemotherapy for relapsed\/refractory primary central nervous system lymphoma: a retrospective analysis of case series. Front Oncol. 2022;12:901797.","journal-title":"Front Oncol"},{"key":"1450_CR31","first-page":"1714","volume":"31","author":"Y Xie","year":"2023","unstructured":"Xie Y, Qu S, Liao LS, Zheng ZH, Lin Y, Chen WM, et al. Evaluation of the short-term efficacy and safety of orelabrutinib combined with high-dose methotrexate in the first-line treatment of elderly patients with high risk primary central nervous system lymphoma. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023;31:1714\u20139.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"1450_CR32","doi-asserted-by":"crossref","unstructured":"Gao Y, Ping L, Shan C, Huang H, Li Z, Zhou H, et al. High-dose methotrexate, ibrutinib, and temozolomide in the treatment of newly diagnosed primary CNS lymphoma: a multicenter, prospective phase-II study. Blood Cancer Discov. 2025;6:191\u2013202.","DOI":"10.1158\/2643-3230.BCD-24-0156"},{"key":"1450_CR33","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1182\/bloodadvances.2024014073","volume":"9","author":"SR Hwang","year":"2025","unstructured":"Hwang SR, Godby RC, Negaard BJ, Mwangi R, Nedved AN, Barreto JN, et al. Comparison of outcomes in postinduction strategies for primary central nervous system lymphoma: a Mayo Clinic experience. Blood Adv. 2025;9:924\u201332.","journal-title":"Blood Adv"},{"key":"1450_CR34","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1038\/s41375-022-01582-5","volume":"36","author":"AJM Ferreri","year":"2022","unstructured":"Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, Celico C, et al. Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia. 2022;36:1870\u20138.","journal-title":"Leukemia"},{"key":"1450_CR35","doi-asserted-by":"publisher","first-page":"e796","DOI":"10.1093\/oncolo\/oyae059","volume":"29","author":"YR Kim","year":"2024","unstructured":"Kim YR, Cho H, Kim SJ, Chung H, Kook HW, Jang JE, et al. Clinical outcomes of etoposide and cytarabine as consolidation in elderly patients with primary CNS lymphoma. Oncologist. 2024;29:e796\u2013e802.","journal-title":"Oncologist"},{"key":"1450_CR36","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1111\/jcmm.12252","volume":"18","author":"D Zhao","year":"2014","unstructured":"Zhao D, Qian L, Shen J, Liu X, Mei K, Cen J, et al. Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma. J Cell Mol Med. 2014;18:1081\u20136.","journal-title":"J Cell Mol Med"},{"key":"1450_CR37","doi-asserted-by":"publisher","first-page":"49156","DOI":"10.18632\/oncotarget.17101","volume":"8","author":"X Sun","year":"2017","unstructured":"Sun X, Liu J, Wang Y, Bai X, Chen Y, Qian J, et al. Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma. Oncotarget. 2017;8:49156\u201364.","journal-title":"Oncotarget"},{"key":"1450_CR38","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1158\/1078-0432.CCR-09-2891","volume":"16","author":"L Zitvogel","year":"2010","unstructured":"Zitvogel L, Kepp O, Senovilla L, Menger L, Chaput N, Kroemer G. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res. 2010;16:3100\u20134.","journal-title":"Clin Cancer Res"},{"key":"1450_CR39","doi-asserted-by":"publisher","first-page":"1085476","DOI":"10.3389\/fimmu.2023.1085476","volume":"14","author":"Z Zhao","year":"2023","unstructured":"Zhao Z, Liu S, Sun R, Zhu W, Zhang Y, Liu T, et al. The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer. Front Immunol. 2023;14:1085476.","journal-title":"Front Immunol"},{"key":"1450_CR40","first-page":"1598","volume":"6","author":"I Bonzheim","year":"2022","unstructured":"Bonzheim I, Sander P, Salmeron-Villalobos J, Susskind D, Szurman P, Gekeler F, et al. The molecular hallmarks of primary and secondary vitreoretinal lymphoma. Blood Adv. 2022;6:1598\u2013607.","journal-title":"Blood Adv"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01450-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01450-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01450-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T05:21:58Z","timestamp":1771564918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01450-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1450"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01450-w","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"10 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by an institutional review board and ethics committee at Jiangsu Province Hospital in accordance with the Declaration of Helsinki (2022-SR-166). All patients gave written informed consent before enrollment. The study is registered on clinicaltrials.gov (NCT05347641). The study protocol is available online.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"23"}}